A monoclonal antibody (WNT-2Ab) against human WNT2 ligand has been developed to induce apoptosis in melanoma cells exerting WNT2 overexpression, and WNT-2Ab treatment downregulated β-catenin target genes, e.g., CCND1 and c-Myc [177]. This evidence concerns the gene WNT2 and melanoma.